Anne Favret

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris et al. · New England Journal of Medicine · 2016 · 1.9K citations · Full text

Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices

Neelima Denduluri, Debra A. Patt, Yunfei Wang et al. · Journal of the National Comprehensive Cancer Network · 2015 · 139 citations · Full text

Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study

Stephen E. Jones, Rufus Collea, Devchand Paul et al. · The Lancet Oncology · 2013 · 134 citations

Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial

Gabe S. Sonke, Lowell L. Hart, Mario Campone et al. · Breast Cancer Research and Treatment · 2017 · 91 citations · Full text

Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study

Denise A. Yardley, James A. Reeves, Elizabeth Claire Dees et al. · Clinical Breast Cancer · 2016 · 32 citations